Laminin-5 stimulates hepatocellular carcinoma growth through a different function of α6β4 and α3β1 integrins

Hepatology

Volumn 46, Issue 6, 2007, Pages 1801-1809

  Bergamini, Carlo ^a   Sgarra, Concetta ^a   Trerotoli, Paolo ^a   Lupo, Luigi ^a   Azzariti, Amalia ^b   Antonaci, Salvatore ^a   Giannelli, Gianluigi ^a,c  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6BETA4 INTEGRIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; KALININ; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VERY LATE ACTIVATION ANTIGEN 3;

AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; INTEGRIN ALPHA3BETA1; INTEGRIN ALPHA6BETA4; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 37749038909     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21936     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.
3. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999;31(Suppl 1):25-30.
4. Nolte M, Werner M, Nasarek A, Bektas H, von Wasielewski R, Klempnauer J, et al. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol 1998;51: 47-51.
5. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-225.
6. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25:3787-3800.
7. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377-1383.
8. Giannelli G, Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol 2006;40: 842-846.
9. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005;129:1375-1383.
10. Burgeson RE, Chiquet M, Deutzmann R, Ekblom P, Engel J, Kleinman H, et al. A new nomenclature for the laminins. Matrix Biol 1994;14:209-211.
11. Giannelli G, Fransvea E, Bergamini C, Marinosci F, Antonaci S. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 2003;9(10 Pt 1):3684-3691.
12. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995;55:4132-4139.
13. Skyldberg B, Salo S, Eriksson E, Aspenblad U, Moberger B, Tryggvason K, et al. Laminin-5 as a marker of invasiveness in cervical lesions. J Natl Cancer Inst 1999;91:1882-1887.
14. Giannelli G, Antonaci S. Biological and clinical relevance of Laminin-5 in cancer. Clin.Exp.Metastasis 2001;18:439-443.
15. Miyazaki K. Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 2006;97:91-98.
16. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5.
17. Carter WG, Kaur P, Gil SG, Gahr PJ, Wayner EA. Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes. J Cell Biol 1990;111(6 Pt 2):3141-3154.
18. Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V, Antonaci S. Human Hepatocellular Carcinoma (HCC) Cells Require Both alpha3beta1 Integrin and Matrix Metalloproteinases Activity for Migration and Invasion. Lab Invest 2001;81:613-627.
19. Plopper G, Falk-Marzillier J, Glaser S, Fitchmun M, Giannelli G, Romano T, et al. Changes in expression of monoclonal antibody epitopes on laminin-5r induced by cell contact. J Cell Sci 1996;109(Pt 7):1965-1973.
20. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000;148:615-624.
21. Ochel HJ. Correlation between crystal violet dissolution assay and manual colony counting on the in vitro effects of Hsp90-inhibitors. J Exp Ther Oncol 2005;5:9-13.
22. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-228.
23. Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17: 485-489.
24. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-6663.
25. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
26. Joly D, Berissi S, Bertrand A, Strehl L, Patey N, Knebelmann B. Laminin 5 regulates polycystic kidney cell proliferation and cyst formation. J Biol Chem 2006;281:29181-29189.
27. Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A. Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer 2004;91:1964-1969.
28. Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khokha R, et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol 2003; 161:197-209.
29. Mainiero F, Pepe A, Yeon M, Ren Y, Giancotti FG. The intracellular functions of alpha6beta4 integrin are regulated by EGF. J Cell Biol 1996; 134:241-253.
30. Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Puri C, Tacchetti C, et al. Targeted deletion of the integrin beta4 signaling domain suppresses laminin-5-dependent nuclear entry of mitogen-activated protein kinases and NF-kappaB, causing defects in epidermal growth and migration. Mol Cell Biol 2005;25:6090-6102.
31. Kariya Y, Tsubota Y, Hirosaki T, Mizushima H, Puzon-McLaughlin W, Takada Y, et al. Differential regulation of cellular adhesion and migration by recombinant laminin-5 forms with partial deletion or mutation within the G3 domain of alpha3 chain. J Cell Biochem 2003;88:506-520.
32. Ogawa T, Tsubota Y, Hashimoto J, Kariya Y, Miyazaki K. The Short Arm of Laminin (gamma)2 Chain of Laminin-5 (Laminin-332) Binds Syndecan-1 and Regulates Cellular Adhesion and Migration by Suppressing Phosphorylation of Integrin {beta}4 Chain. Mol Biol Cell 2007.